Wall Street brokerages forecast that Unity Biotechnology, Inc. (NASDAQ:UBX) will report earnings per share of ($0.38) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Unity Biotechnology’s earnings. The highest EPS estimate is ($0.37) and the lowest is ($0.38). Unity Biotechnology posted earnings per share of ($0.54) in the same quarter last year, which would indicate a positive year over year growth rate of 29.6%. The company is scheduled to report its next quarterly earnings report on Thursday, May 6th.
According to Zacks, analysts expect that Unity Biotechnology will report full-year earnings of ($1.53) per share for the current financial year, with EPS estimates ranging from ($1.63) to ($1.47). For the next financial year, analysts forecast that the business will post earnings of ($1.21) per share. Zacks’ EPS calculations are an average based on a survey of research firms that follow Unity Biotechnology.
Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings results on Monday, March 22nd. The company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.10.
NASDAQ:UBX traded down $0.29 during midday trading on Thursday, reaching $4.58. The stock had a trading volume of 29,713 shares, compared to its average volume of 695,071. The firm’s fifty day simple moving average is $5.85 and its 200-day simple moving average is $5.90. The stock has a market capitalization of $250.52 million, a P/E ratio of -2.36 and a beta of 0.36. Unity Biotechnology has a 1-year low of $2.72 and a 1-year high of $15.44.
Institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in Unity Biotechnology in the third quarter valued at approximately $36,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Unity Biotechnology in the 4th quarter valued at $43,000. Fort Point Capital Partners LLC acquired a new position in shares of Unity Biotechnology during the fourth quarter valued at about $52,000. Engineers Gate Manager LP bought a new position in Unity Biotechnology in the fourth quarter worth approximately $54,000. Finally, Principal Financial Group Inc. bought a new position in shares of Unity Biotechnology in the 4th quarter worth $56,000. 37.21% of the stock is currently owned by institutional investors.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.